Bosutinib
- TRADE NAME: Bosulif (Wyeth)
- INDICATIONS: Chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia in adult patients with resistance or intolerance to prior therapy
- CLASS: Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 23 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inhibitors (strong or moderate), Digoxin, Ketoconazole, Lansoprazole, P-glycoprotein inhibitors, Proton pump inhibitors
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of bosutinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/25/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric